

(51) International Patent Classification:
A61K 39/12 (2006.01)(21) International Application Number:
PCT/EP2021/068879(22) International Filing Date:
07 July 2021 (07.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/049,400 08 July 2020 (08.07.2020) US
63/144,051 01 February 2021 (01.02.2021) US(71) Applicant: **JANSSEN SCIENCES IRELAND UN-
LIMITED COMPANY** [IE/IE]; Barnahely Ringaskiddy,
Co Cork (IE).(72) Inventors: **DEHART, Jason L.**; c/o Janssen Biotech, Inc.,
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US). **WANG, Nathaniel Stephen**; c/o Janssen Pharmaceu-
ticals, Inc., 1125 Trenton-Harbourton Road, Titusville, New
Jersey 08560 (US). **ALIAHMAD, Parinaz**; c/o Janssen
Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Ti-
tusville, New Jersey 08560 (US). **MAINE, Christian**; c/
o Janssen Biotech, Inc., 800/850 Ridgeview Drive, Hor-sham, Pennsylvania 19044 (US). **DAVIS, Heather Lynn**;
c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340
Beerse (BE). **PACE, Craig**; c/o Janssen Biotech, Inc.,
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).(74) Agent: **DUFFIELD, Stephen** et al.; Carpmaels & Ransford
LLP, One Southampton Row, London WC1B 5HA (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: RNA REPLICON VACCINES AGAINST HBV




FIG. 1A




FIG. 1B

(57) Abstract: Nucleic acid molecules encoding hepatitis B virus (HBV) surface anti-
gens, HBV core antigens, and HBV polymerase antigens, and related combinations,
are described. Also described are vectors, such as DNA plasmids or viral vectors,
and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions
containing the expression vectors. Methods of inducing an immune response against
HBV or treating an HBV-induced disease, particularly in individuals having chron-
ic HBV infection, using the pharmaceutical compositions of the invention are also
described.

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*